VEGFA and neoplasm: With the beneficial effect of BPC 157 therapy, this can occur along with blocking VEGF signaling during the “angiogenic switch” and initial tumor growth [95] and the counteraction of severe adverse effects occurring with cytostatic drug applications [180,181,182], thereby improving their anti-tumor effectiveness.